Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR-02 pancreatic endocrine cell clusters in type 1 diabetes
NCT06651515Phase 2Withdrawn
- Sponsor
- Seraxis
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SR-02 in type 1 diabetes mellitus (T1D), sponsored by Seraxis. Primary endpoints: Treatment Emergent Adverse Events and Serious Adverse Events at 365 days and 90-minute MMTT-stimulated C-peptide at 365 days. Planned start Apr 2025; status: withdrawn.
02
Drugs
SR-02
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06651515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651515.